Blog

Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background
Slide background

Kinomica

Kinomica’s mission is to provide competitive intelligence to enhance tailored treatment decisions involving anticancer drug therapies. Its next generation biomarkers will deliver superior diagnostics and services, thereby enabling precision therapeutics.

 

There is a widely acknowledged, valuable and rising marketplace (estimated to reach $36 billion in 2018) for clinical biomarkers and diagnostics that determine a patients’ response to anticancer therapies. Although several competitive approaches are being pursued, today’s leading diagnostic tools focus on interventions made possible by advances derived from the application of DNA and RNA-based technologies. Whilst some have met with success there is a growing literature that suggests that this approach is not free of significant limitations (Figure 9).  Kinomica’s whole kinome vetting approach derives from the application of highly instructive, content rich, proprietary technologies using phosphoproteomics mass spectrometry. Recent clinical proof of concept studies that enabled side-by-side comparisons cast doubt on some of the conclusions reached using DNA/RNA diagnostic technology. But of greater significance Kinomica’s approaches can forecast, not only whether a patient will or will not respond to a therapeutic intervention with a specific drug, but also predict which of the alternative therapeutic options is likely to achieve greater success in an individual patient (Figure 10). This powerful, validated, unique selling proposition may be applied for both drug selection and ongoing drug monitoring during active therapy.

 

At launch the proposition is to deliver the technology both for market testing and validation purposes via specimen testing and analysis at designated drug reference laboratories.  Contrary to initial expectations this is proving to be an attractive commercial model adopted by several diagnostic companies, e.g., Genomic Health (Market Cap $1.1 billion).  Kinomica’s test reports can be produced in less than 10 days. This is well within the clinical treatment decision-making process time for cancer. The initial market entrants to emerge from the company’s R&D strategy will focus on blood tumours with subsequent product launches addressing other disease states.

www.innovation.qmul.ac.uk